PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Novo Nordisk A/S (NOV.DE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINDK0062498333
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap€450.59B
EPS (TTM)€2.84
PE Ratio35.56
PEG Ratio1.64
Total Revenue (TTM)€85.63B
Gross Profit (TTM)€72.69B
EBITDA (TTM)€44.45B
Year Range€80.20 - €134.50

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons: NOV.DE vs. TM2.F, NOV.DE vs. 4AB.DE, NOV.DE vs. NVO, NOV.DE vs. LLY, NOV.DE vs. VOO, NOV.DE vs. FICO, NOV.DE vs. AMAT, NOV.DE vs. CSP1.L, NOV.DE vs. QCOM, NOV.DE vs. ARM

Performance

Performance Chart

The chart shows the growth of an initial investment of €10,000 in Novo Nordisk A/S, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%-10.00%0.00%10.00%20.00%JuneJulyAugustSeptemberOctoberNovember
-12.60%
16.37%
NOV.DE (Novo Nordisk A/S)
Benchmark (^GSPC)

Returns By Period

Novo Nordisk A/S had a return of 19.80% year-to-date (YTD) and 21.07% in the last 12 months. Over the past 10 years, Novo Nordisk A/S had an annualized return of 43.32%, outperforming the S&P 500 benchmark which had an annualized return of 11.43%.


PeriodReturnBenchmark
Year-To-Date19.80%25.82%
1 month-5.66%3.20%
6 months-12.60%14.94%
1 year21.07%35.92%
5 years (annualized)48.08%14.22%
10 years (annualized)43.32%11.43%

Monthly Returns

The table below presents the monthly returns of NOV.DE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202412.54%4.32%15.05%-0.17%3.62%8.38%-9.19%5.64%-15.43%-3.13%19.80%
2023-0.22%5.03%16.53%3.47%-0.72%-1.93%-0.58%21.27%0.91%5.26%2.58%0.64%62.65%
2022-10.29%3.68%17.96%8.56%-6.42%3.50%7.76%-3.33%-3.36%7.84%7.87%6.70%44.14%
2021-1.60%3.05%11.67%3.99%6.11%9.12%10.07%12.49%-0.85%13.20%0.06%4.30%97.72%
20205.84%-4.59%17.09%5.46%0.57%-0.89%-4.44%5.35%6.96%-6.25%1.90%2.82%31.45%
20193.72%4.87%22.37%-6.42%-2.95%5.89%-3.29%16.88%0.05%3.52%3.13%3.06%59.27%
2018-0.37%-4.82%41.27%-2.24%3.69%-2.26%8.03%6.13%-3.85%-5.90%6.96%-3.30%42.41%
2017-3.11%1.19%12.22%10.87%5.62%-0.81%-3.64%20.02%1.64%5.31%0.97%3.88%65.94%
2016-4.62%-6.27%14.24%2.24%2.85%-3.67%5.78%-11.69%-11.46%-12.22%-2.07%7.37%-21.03%
201511.74%6.92%31.09%1.35%1.91%-3.56%8.40%-7.75%-2.36%0.87%7.22%2.68%69.12%
201410.53%18.36%9.80%-1.94%-3.90%8.18%2.40%1.18%9.76%-5.36%0.95%-2.48%55.15%
201310.37%-0.67%8.77%5.47%-6.05%-2.00%4.13%-1.61%-0.36%-1.60%7.27%0.76%25.73%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of NOV.DE is 62, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of NOV.DE is 6262
Combined Rank
The Sharpe Ratio Rank of NOV.DE is 6464Sharpe Ratio Rank
The Sortino Ratio Rank of NOV.DE is 5959Sortino Ratio Rank
The Omega Ratio Rank of NOV.DE is 5555Omega Ratio Rank
The Calmar Ratio Rank of NOV.DE is 7272Calmar Ratio Rank
The Martin Ratio Rank of NOV.DE is 6161Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Novo Nordisk A/S (NOV.DE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


NOV.DE
Sharpe ratio
The chart of Sharpe ratio for NOV.DE, currently valued at 0.81, compared to the broader market-4.00-2.000.002.004.000.81
Sortino ratio
The chart of Sortino ratio for NOV.DE, currently valued at 1.35, compared to the broader market-4.00-2.000.002.004.006.001.35
Omega ratio
The chart of Omega ratio for NOV.DE, currently valued at 1.17, compared to the broader market0.501.001.502.001.17
Calmar ratio
The chart of Calmar ratio for NOV.DE, currently valued at 0.95, compared to the broader market0.002.004.006.000.95
Martin ratio
The chart of Martin ratio for NOV.DE, currently valued at 2.56, compared to the broader market0.0010.0020.0030.002.56
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 3.08, compared to the broader market-4.00-2.000.002.004.003.08
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 4.10, compared to the broader market-4.00-2.000.002.004.006.004.10
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.58, compared to the broader market0.501.001.502.001.58
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 4.48, compared to the broader market0.002.004.006.004.48
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 20.05, compared to the broader market0.0010.0020.0030.0020.05

Sharpe Ratio

The current Novo Nordisk A/S Sharpe ratio is 0.81. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Novo Nordisk A/S with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.501.001.502.002.503.00JuneJulyAugustSeptemberOctoberNovember
0.81
2.97
NOV.DE (Novo Nordisk A/S)
Benchmark (^GSPC)

Dividends

Dividend History

Novo Nordisk A/S provided a 1.28% dividend yield over the last twelve months, with an annual payout of €1.33 per share. The company has been increasing its dividends for 4 consecutive years.


1.00%2.00%3.00%4.00%5.00%6.00%€0.00€0.20€0.40€0.60€0.80€1.00€1.2020132014201520162017201820192020202120222023
Dividends
Dividend Yield
PeriodTTM20232022202120202019201820172016201520142013
Dividend€1.33€0.95€0.75€0.63€0.58€0.55€1.18€0.51€0.63€0.34€0.30€0.24

Dividend yield

1.28%1.01%1.18%1.27%1.99%2.09%5.96%2.28%3.69%1.25%1.69%1.82%

Monthly Dividends

The table displays the monthly dividend distributions for Novo Nordisk A/S. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024€0.00€0.00€0.86€0.00€0.00€0.00€0.00€0.47€0.00€0.00€0.00€1.33
2023€0.00€0.00€0.55€0.00€0.00€0.00€0.00€0.40€0.00€0.00€0.00€0.00€0.95
2022€0.00€0.00€0.46€0.00€0.00€0.00€0.00€0.29€0.00€0.00€0.00€0.00€0.75
2021€0.00€0.00€0.39€0.00€0.00€0.00€0.00€0.24€0.00€0.00€0.00€0.00€0.63
2020€0.00€0.00€0.36€0.00€0.00€0.00€0.00€0.22€0.00€0.00€0.00€0.00€0.58
2019€0.00€0.00€0.34€0.00€0.00€0.00€0.00€0.20€0.00€0.00€0.00€0.00€0.55
2018€0.00€0.00€0.98€0.00€0.00€0.00€0.00€0.20€0.00€0.00€0.00€0.00€1.18
2017€0.00€0.00€0.31€0.00€0.00€0.00€0.00€0.20€0.00€0.00€0.00€0.00€0.51
2016€0.00€0.00€0.43€0.00€0.00€0.00€0.00€0.20€0.00€0.00€0.00€0.00€0.63
2015€0.00€0.00€0.34€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.34
2014€0.00€0.00€0.30€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.30
2013€0.24€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.00€0.24

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%1.3%
Novo Nordisk A/S has a dividend yield of 1.28%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
200.0%400.0%600.0%800.0%4.9%
Novo Nordisk A/S has a payout ratio of 4.90%, which is below the market average. This means Novo Nordisk A/S returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-25.00%-20.00%-15.00%-10.00%-5.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-22.94%
0
NOV.DE (Novo Nordisk A/S)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Novo Nordisk A/S. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Novo Nordisk A/S was 50.94%, occurring on Jul 24, 2002. Recovery took 358 trading sessions.

The current Novo Nordisk A/S drawdown is 22.94%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-50.94%Apr 2, 200279Jul 24, 2002358Feb 9, 2004437
-37.74%Aug 2, 201681Nov 23, 2016187Aug 18, 2017268
-29.53%Apr 9, 2008129Oct 10, 2008150May 22, 2009279
-26.37%Jun 26, 202497Nov 7, 2024
-25.59%Aug 6, 2015130Feb 9, 201629Mar 21, 2016159

Volatility

Volatility Chart

The current Novo Nordisk A/S volatility is 5.71%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%JuneJulyAugustSeptemberOctoberNovember
5.71%
5.51%
NOV.DE (Novo Nordisk A/S)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Novo Nordisk A/S over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of Novo Nordisk A/S compared to its peers in the Biotechnology industry.


PE Ratio
200.0400.0600.0800.035.6
The chart displays the price to earnings (P/E) ratio for NOV.DE in comparison to other companies of the Biotechnology industry. Currently, NOV.DE has a PE value of 35.6. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.
PEG Ratio
-1,000.0-800.0-600.0-400.0-200.00.01.6
The chart displays the price to earnings to growth (PEG) ratio for NOV.DE in comparison to other companies of the Biotechnology industry. Currently, NOV.DE has a PEG value of 1.6. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Novo Nordisk A/S.


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items